Skip to main content
. Author manuscript; available in PMC: 2012 Sep 1.
Published in final edited form as: Biol Blood Marrow Transplant. 2011 Jan 11;17(9):1308–1315. doi: 10.1016/j.bbmt.2011.01.004

Table 3.

Outcomes after DLI plus IL-2 Therapy

Study Case # IL-2 Dose Level GVHD after DLI
Study Toxicity* Remission after DLI Remission Duration after DLI (Months)
Acute Chronic
Acute myeloid leukemia
 2 I 0 NA N N
 3 I III Extensive N Y 33
 5 I III Extensive N Y 35
 17 I 0 Extensive N N
 7 Ia 0 NA N N
 8 Ia 0 0 N N
 10 Ia II Extensive N Y 9
 11 Ia 0 Extensive N Y 5
 12 Ia IV Extensive Y (GVHD) Y 47
 14 Ia 0 0 N Y 6
 15 Ia 0 0 N Y 3
Acute lymphoblastic leukemia
 1 I 0 0 N N
 4 I III Extensive Y (GVHD) Y 8
 16 I 0 0 N Y 5
 9 Ia 0 Limited N N
 13 Ia III Extensive Y (IL2) Y 12
 6 II 0 NA Y (IL-2) N

GVHD indicates graft-versus-host disease; DLI, donor lymphocyte infusion; N, no; Y, yes; NA, not assessable.

*

Death related to acute or chronic GVHD, development of acute or chronic GVHD with inability to decrease the dose of prednisone to less than 1mg/kg/day within 1 month after initiating treatment for GVHD, or life threatening or fatal organ toxicity attributable to IL-2.

Also remission before DLI following chemotherapy.